Health and Healthcare

How Analysts View Pfizer and Merck After Earnings

Thinkstock

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) released their most recent earnings reports last week. As a result, analysts weighed in on both of these pharmaceutical giants. 24/7 Wall St. included some of the highlights from the earnings reports, as well as brief analyst montages.

Pfizer reported quarterly adjusted diluted earnings per share (EPS) of $0.53 and revenues of $14.05 billion. In the same period a year ago, Pfizer reported EPS of $0.54 on revenues of $13.12 billion. Fourth-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $0.52 and $13.56 billion in revenues.

Quarterly revenues were up 7% year over year on strong operational growth, partially offset by a 7% negative impact from foreign exchange rates. Excluding the effects of its Hospira acquisition, foreign exchange rates and revenues from vaccine acquisitions, fourth-quarter revenues rose 5%.

The company guided 2016 revenues in a range of $49 billion to $51 billion and adjusted EPS in a range of $2.20 to $2.30. At constant currency rates, revenues are forecast in a range of $51.3 billion to $53.3 billion and adjusted EPS is expected to fall in a range of $2.36 to $2.46. Foreign exchange rates are expected to cost the company $0.09 per share in 2016, and Venezuelan foreign exchange rates are expected to cost Pfizer another $0.07. The proposed merger with Allergan has no impact on the company’s outlook.

Analysts had been looking for 2016 EPS of $2.36 and revenues of $52.49 billion, and Pfizer’s forecast, including currency effects, is lower than expected.

A few analysts weighed in on Pfizer after the earnings report:

  • Credit Suisse lowered its price target to $38 from $41.
  • Deutsche Bank has a Buy rating and lowered its price target from $43 to $41.
  • Bernstein has an Outperform rating but lowered its price target to $36 from $41.
  • BMO Capital Markets reiterated an Outperform rating and lowered its price target to $39 from $41.

Shares of Pfizer closed Friday at $29.03, with a consensus analyst price target of $39.63 and a 52-week trading range of $28.47 to $36.46.


Merck had $0.93 in EPS on $10.21 billion in revenue, which compares to consensus estimates of $0.91 in EPS on revenue of $10.35 billion. In the same period of the previous year, the pharmaceutical giant posted EPS of $0.87 and $10.48 billion in revenue.

In the fourth quarter, revenues decreased by 3% compared with last year, including a 7% negative impact from foreign exchange and a 3% net positive impact primarily from the acquisition of Cubist Pharmaceuticals.

Also in the fourth quarter, Merck significantly advanced its development program for Keytruda (pembrolizumab), an anti-PD-1 therapy for the treatment of metastatic non-small cell lung cancer in previously treated patients whose tumors express PD-L1, as well as advanced melanoma.

In terms of the outlook for 2016, Merck expects EPS to be in the range of $3.60 to $3.75 and revenues between $38.7 billion and $40.2 billion. The consensus estimates call for $3.72 in EPS on $40.25 in revenue for the full year.

A few analysts weighed in on Merck following the release of its earnings report:

  • S&P Equity Research reiterated a Hold rating with a $56 price target.
  • Credit Suisse lowered its price target to $56 from $59.
  • Goldman Sachs has a Neutral rating but lowered its price target from $60 to $56.
  • BMO Capital Markets has an Outperform rating and lowered its price target to $58 from $60.

Shares of Merck closed Friday at $49.38, with a consensus price target of $60.11 and a 52-week range of $45.69 to $61.70.

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.